Table 4.
Multivariable Adjusted1 Risk of Incident Symptoms at Post-Stopping2 by Prevalence of Baseline Symptoms3: WHI CEE sub-sample (n=3496)4
| Symptom Prevalence at Baseline | CEE %5 (N6) | Placebo % (N) | RR (95% CI)7 | P8 | P-int9 |
|---|---|---|---|---|---|
| Hot Flashes | |||||
| Without Symptoms | 7.2 (1471) | 1.5 (1562) | 5.01 (3.12, 8.04) | <0.001 | <0.001 |
| With Symptoms | 28.6 (217) | 19.9 (181) | 1.30 (0.90, 1.88) | ||
| Night sweats | |||||
| Without Symptoms | 8.0 (1454) | 3.8 (1557) | 1.95 (1.42, 2.67) | <0.001 | 0.13 |
| With Symptoms | 31.3 (224) | 23.0 (178) | 1.35 (0.96, 1.90) | ||
| Breast Tenderness | |||||
| Without Symptoms | 2.2 (1653) | 1.6 (1716) | 1.53 (0.90, 2.58) | 0.04 | 0.19 |
| With Symptoms | 17.1 (35) | 3.6 (28) | 4.79 (0.63, 6.66) | ||
| Vaginal Dryness | |||||
| Without Symptoms | 3.2 (1519) | 3.3 (1582) | 0.86 (0.57, 1.30) | 0.89 | 0.31 |
| With Symptoms | 24.4 (160) | 19.9 (151) | 1.17 (0.77, 1.77) | ||
| Joint Pain | |||||
| Without Symptoms | 22.2 (1211) | 17.3 (1252) | 1.35 (1.13, 1.60) | <0.001 | 0.07 |
| With Symptoms | 59.6 (465) | 51.2 (494) | 1.11 (0.98, 1.25) | ||
| Mood Swings | |||||
| Without Symptoms | 4.1 (1563) | 3.1 (1640) | 1.33 (0.90, 1.96) | 0.51 | 0.10 |
| With Symptoms | 22.1 (113) | 25.7 (105) | 0.77 (0.46, 1.29) | ||
1
Adjusted for age at baseline, years since menopause and prior hormone use.
2
Incidence of moderate or severe symptoms after stopping study pills.
3
Prevalence of moderate or severe symptoms at baseline.
4
Women that were eligible (were not deceased, stopped or lost to follow-up and were still taking study pills) and completed all surveys.
5
Proportion of N reporting symptoms post-stopping.
6
N= total number of participants; denominator of (5).
7
Multivariable adjusted relative risk (95% confidence interval) of symptoms at post-stopping of CEE compared to placebo.
8
Test of main effect.
9
Test of interaction.